BioCentury | Oct 31, 2020
Deals

Oct. 30 Quick Takes: Q32 raises B round; plus CStone-LegoChem, Centrexion, Sidekick

...are no ADCs targeting ROR1 on the market, but at least three are in clinical development.Centrexion...
...Interleukin-7 receptorROR1 – Receptor tyrosine kinase-like orphan receptor 1 BC Staff CStone Pharmaceuticals Co. Ltd. Q32 Bio Inc. Centrexion Therapeutics Corp. LegoChem...
BioCentury | Aug 6, 2020
Management Tracks

Kindler joins Blackstone as senior adviser; plus changes at Mission, Annexon, Dyne, Ribometrix, Autolus and more

...Jeffrey Kindler has joined Blackstone Group as a senior adviser. He is the CEO of Centrexion Therapeutics Corp....
BioCentury | Jul 16, 2020
Management Tracks

NextCure CMO Heller to resign; plus Vertex, Turning Point, Scholar Rock, C4, Vor and more

...as EVP and chief commercial officer, a new position. He was CCO and COO of Centrexion Therapeutics Corp....
BioCentury | Oct 4, 2019
Finance

Biotechs likely to flood IPO market ahead of 2020 election

...Inc. (HKEX) 4/18/19 TBD Mkt (drug) Cirius Therapeutics Inc. 1/11/19 Up to $86.3 Ph II Centrexion Therapeutics Corp....
BioCentury | Sep 23, 2019
Financial News

Fall IPO flurry as biotechs ramp up listing timelines

...Stanley and RBC Capital Markets. Also lining up in the IPO queue is pain company Centrexion Therapeutics...
...18. Led by CEO Jeffrey Kindler, a former chairman and CEO of Pfizer Inc. (NYSE:PFE), Centrexion...
...pain; it partnered another investigational analgesic with Eli Lilly and Co. (NYSE:LLY) in May (see "Centrexion...
BioCentury | Sep 5, 2019
Financial News

Quan doubles down with new $250M fund

...for the same amount. It also invested in a $67 million series D round for Centrexion Therapeutics Corp....
...former VP and site head of Roche Innovation Center Shanghai. Xu is on Tempest's and Centrexion's...
...on Crescendo's (see “Versant Launches Tempest With $70M,” “Andera Leads Crescendo’s $70M Series B” and “Centrexion...
BioCentury | May 28, 2019
Company News

Months after scuttling IPO bid, Centrexion adds to balance sheet with Lilly deal for pain therapy

...analgesic will bolster Centrexion's balance sheet six months after it canceled plans for an IPO. Centrexion...
...of Pfizer Inc. (NYSE:PFE) in 2006-10. Centrexion did not respond to inquiries Tuesday. In November, Centrexion...
...operating loss of $24 million (see “Centrexion Steps Back From IPO Amid Volatile Market” ). Centrexion...
BioCentury | Jan 12, 2019
Finance

Warning: cash needed

...Biotechnology Co. Ltd. (HKEX) 10/30/18 TBD Mkt (vaccine) Accelerated Pharma Inc. 10/22/18 $3M Ph III Centrexion Therapeutics Corp....
BioCentury | Dec 7, 2018
Financial News

Moderna sets IPO record with upsized $604M offering

...lower valuations than they would have received at the midpoint of their proposed range (see "Centrexion...
BioCentury | Nov 30, 2018
Financial News

Centrexion steps back from IPO amid volatile market

...BTK) have each experienced multiple daily swings of at least 2% in either direction since Centrexion...
...midpoint, the IPO would have raised $75 million and valued the company at $332.4 million. Centrexion...
...$42 million in cash and a nine-month operating loss of $24 million. Centrexion Therapeutics Corp., Boston, Mass. Alicia Parker Centrexion Therapeutics Corp....
Items per page:
1 - 10 of 30
BioCentury | Oct 31, 2020
Deals

Oct. 30 Quick Takes: Q32 raises B round; plus CStone-LegoChem, Centrexion, Sidekick

...are no ADCs targeting ROR1 on the market, but at least three are in clinical development.Centrexion...
...Interleukin-7 receptorROR1 – Receptor tyrosine kinase-like orphan receptor 1 BC Staff CStone Pharmaceuticals Co. Ltd. Q32 Bio Inc. Centrexion Therapeutics Corp. LegoChem...
BioCentury | Aug 6, 2020
Management Tracks

Kindler joins Blackstone as senior adviser; plus changes at Mission, Annexon, Dyne, Ribometrix, Autolus and more

...Jeffrey Kindler has joined Blackstone Group as a senior adviser. He is the CEO of Centrexion Therapeutics Corp....
BioCentury | Jul 16, 2020
Management Tracks

NextCure CMO Heller to resign; plus Vertex, Turning Point, Scholar Rock, C4, Vor and more

...as EVP and chief commercial officer, a new position. He was CCO and COO of Centrexion Therapeutics Corp....
BioCentury | Oct 4, 2019
Finance

Biotechs likely to flood IPO market ahead of 2020 election

...Inc. (HKEX) 4/18/19 TBD Mkt (drug) Cirius Therapeutics Inc. 1/11/19 Up to $86.3 Ph II Centrexion Therapeutics Corp....
BioCentury | Sep 23, 2019
Financial News

Fall IPO flurry as biotechs ramp up listing timelines

...Stanley and RBC Capital Markets. Also lining up in the IPO queue is pain company Centrexion Therapeutics...
...18. Led by CEO Jeffrey Kindler, a former chairman and CEO of Pfizer Inc. (NYSE:PFE), Centrexion...
...pain; it partnered another investigational analgesic with Eli Lilly and Co. (NYSE:LLY) in May (see "Centrexion...
BioCentury | Sep 5, 2019
Financial News

Quan doubles down with new $250M fund

...for the same amount. It also invested in a $67 million series D round for Centrexion Therapeutics Corp....
...former VP and site head of Roche Innovation Center Shanghai. Xu is on Tempest's and Centrexion's...
...on Crescendo's (see “Versant Launches Tempest With $70M,” “Andera Leads Crescendo’s $70M Series B” and “Centrexion...
BioCentury | May 28, 2019
Company News

Months after scuttling IPO bid, Centrexion adds to balance sheet with Lilly deal for pain therapy

...analgesic will bolster Centrexion's balance sheet six months after it canceled plans for an IPO. Centrexion...
...of Pfizer Inc. (NYSE:PFE) in 2006-10. Centrexion did not respond to inquiries Tuesday. In November, Centrexion...
...operating loss of $24 million (see “Centrexion Steps Back From IPO Amid Volatile Market” ). Centrexion...
BioCentury | Jan 12, 2019
Finance

Warning: cash needed

...Biotechnology Co. Ltd. (HKEX) 10/30/18 TBD Mkt (vaccine) Accelerated Pharma Inc. 10/22/18 $3M Ph III Centrexion Therapeutics Corp....
BioCentury | Dec 7, 2018
Financial News

Moderna sets IPO record with upsized $604M offering

...lower valuations than they would have received at the midpoint of their proposed range (see "Centrexion...
BioCentury | Nov 30, 2018
Financial News

Centrexion steps back from IPO amid volatile market

...BTK) have each experienced multiple daily swings of at least 2% in either direction since Centrexion...
...midpoint, the IPO would have raised $75 million and valued the company at $332.4 million. Centrexion...
...$42 million in cash and a nine-month operating loss of $24 million. Centrexion Therapeutics Corp., Boston, Mass. Alicia Parker Centrexion Therapeutics Corp....
Items per page:
1 - 10 of 30